Gil Roth07.29.11
Amgen 2Q11
2Q Revenues: $4.0 billion (+4%)
2Q Earnings: $1.2 billion (-3%)
YTD Revenues: $7.7 billion (+4%)
YTD Earnings: $2.3 billion (-3%)
Comments: Product revenues grew 8% in 2Q11 to $3.9 billion. U.S. sales rose 7% to $2.8 billion while international sales were up 11% to $918 million, with 4% accounted for by exchange rates. Epogen and Aranesp sales both fell in 2Q, offset by growth in Neulasta sales (+18% to $1.0 billion) and Enbrel (+9% to $1.0 billion). The company's two denosumab products, Prolia and Xgeva, posted sales of $44 million and $73 million, respectively.
2Q Revenues: $4.0 billion (+4%)
2Q Earnings: $1.2 billion (-3%)
YTD Revenues: $7.7 billion (+4%)
YTD Earnings: $2.3 billion (-3%)
Comments: Product revenues grew 8% in 2Q11 to $3.9 billion. U.S. sales rose 7% to $2.8 billion while international sales were up 11% to $918 million, with 4% accounted for by exchange rates. Epogen and Aranesp sales both fell in 2Q, offset by growth in Neulasta sales (+18% to $1.0 billion) and Enbrel (+9% to $1.0 billion). The company's two denosumab products, Prolia and Xgeva, posted sales of $44 million and $73 million, respectively.